59.22

2.47% 1.43

After Hours: 59.22

Royalty Pharma Plc (RPRX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Royalty Pharma Plc stock is traded at $59.22, with a volume of 3.92M. It is up +2.47% in the last 24 hours and up +4.94% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Previous Close:

$57.79

Open:

$57.75

24h Volume:

3.92M

Relative Volume:

1.11

Market Cap:

$26.37B

Revenue:

$2.44B

Net Income/Loss:

$1.36B

P/E Ratio:

31.02

EPS:

1.9093

Net Cash Flow:

$574.14M

1W Performance:

+2.55%

1M Performance:

+4.94%

6M Performance:

+32.19%

1Y Performance:

+65.14%

1-Day Range:

$57.65

$59.33

1-Week Range:

$56.53

$59.33

52-Week Range:

$34.08

$60.44

Royalty Pharma Plc Stock (RPRX) Company Profile

Name

Royalty Pharma Plc

Sector

Healthcare (1075)

Industry

Biotechnology (600)

Phone

(212) 883-0200

Address

110 EAST 59TH STREET, NEW YORK, NY

Employee

100

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

RPRX's Discussions on Twitter

Compare RPRX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RPRX Royalty Pharma Plc	59.22	25.73B	2.44B	1.36B	574.14M	1.9093
VRTX Vertex Pharmaceuticals Inc	525.73	134.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	797.99	82.06B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	876.00	54.10B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	205.26	44.06B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	359.05	40.64B	5.76B	514.49M	1.10B	4.4813

Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-26	Upgrade	UBS	Neutral → Buy
Sep-30-25	Initiated	Goldman	Buy
May-16-25	Initiated	Morgan Stanley	Overweight
Jun-03-24	Downgrade	UBS	Buy → Neutral
Jun-14-22	Resumed	UBS	Buy
May-13-22	Initiated	Scotiabank	Sector Outperform
Apr-27-22	Initiated	Goldman	Buy
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight
Apr-06-22	Resumed	Morgan Stanley	Overweight
Oct-29-21	Upgrade	Citigroup	Neutral → Buy
Jul-30-21	Initiated	Tigress Financial	Buy
Nov-09-20	Upgrade	UBS	Neutral → Buy
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	BofA Securities	Buy
Jul-13-20	Initiated	Citigroup	Neutral
Jul-13-20	Initiated	Cowen	Outperform
Jul-13-20	Initiated	Goldman	Neutral
Jul-13-20	Initiated	JP Morgan	Neutral
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight
Jul-13-20	Initiated	SunTrust	Buy
Jul-13-20	Initiated	UBS	Neutral

View All

Royalty Pharma Plc Stock (RPRX) Latest News

Aug 12, 2026

Royalty Pharma (RPRX) files to potentially sell 11.9M Class A shares - Stock Titan

Aug 12, 2026

RPRX (RPRX) investor files to sell 125,000 Class A shares on NASDAQ - Stock Titan

Aug 12, 2026

Zealand gains $100M in funding from Royalty Pharma (RPRX:NASDAQ) - Seeking Alpha

Aug 12, 2026

Zealand Pharma sells rusfertide royalty rights for $100 million - Investing.com

Aug 12, 2026

Zealand Pharma sells rusfertide royalty rights for $100 million By Investing.com - Investing.com UK

Aug 12, 2026

Behavioral Patterns of RPRX and Institutional Flows - Stock Traders Daily

Aug 12, 2026

A potential blood-disorder therapy is at the center of a $100M deal - Stock Titan

Aug 12, 2026

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide - The Manila Times

Aug 12, 2026